Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
50,000
Stocks News & Analysis
stocks
Higher credit stress for big four bank
Shares fall after announcement that capital will be replenished for loan impairment provisions.
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,177.10 | 16.10 | -0.18% |
| CAC 40 | 8,235.72 | 95.32 | -1.14% |
| DAX 40 | 24,270.87 | 146.93 | -0.60% |
| Dow JONES (US) | 49,402.16 | 40.40 | -0.08% |
| FTSE 100 | 10,498.09 | 110.99 | -1.05% |
| HKSE | 26,487.48 | 126.41 | 0.48% |
| NASDAQ | 24,370.21 | 34.19 | -0.14% |
| Nikkei 225 | 59,349.17 | 873.27 | 1.49% |
| NZX 50 Index | 12,932.33 | 26.66 | 0.21% |
| S&P 500 | 7,094.60 | 14.54 | -0.20% |
| S&P/ASX 200 | 8,949.40 | 20.10 | -0.22% |
| SSE Composite Index | 4,085.08 | 2.95 | 0.07% |